Article
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
Scientific reports - 27 Jul 2022
Bieberich Andrew A, Laitinen Tuomo, Maffuid Kaitlyn, Fatig Raymond O, Torrice Chad D, Morris David C, Crona Daniel J, Asquith Christopher R M
Abstract excerpt
The 4-anilinoquin(az)oline is a well-known kinase inhibitor scaffold incorporated in clinical inhibitors including gefitinib, erlotinib, afatinib, and lapatinib, all of which have previously demonstrated activity against chordoma cell lines in vitro. We screened a focused array of compounds based on the 4-anilinoquin(az)oline scaffold against both U-CH1 and the epidermal growth factor receptor (EGFR) inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.